Profile data is unavailable for this security.
About the company
MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.
- Revenue in USD (TTM)0.00
- Net income in USD-12.78m
- Incorporated2020
- Employees3.00
- LocationMira Pharmaceuticals Inc1200 Brickell Avenue, Suite 1950 #1183MIAMI 33131United StatesUSA
- Phone+1 (813) 369-5150
- Websitehttps://mirapharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spruce Biosciences Inc | 7.10m | -39.43m | 21.72m | 22.00 | -- | 0.4206 | -- | 3.06 | -0.9598 | -0.9598 | 0.1728 | 1.25 | 0.0798 | -- | -- | 244,862.10 | -44.28 | -41.24 | -55.51 | -46.49 | -- | -- | -555.23 | -1,774.39 | -- | -121.12 | 0.0399 | -- | -- | -- | -3.77 | -- | -- | -- |
| HST Global Inc | 0.00 | -123.45k | 22.03m | 1.00 | -- | -- | -- | -- | -0.0209 | -0.0209 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -3,300.80 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -27.31 | 5.81 | -- | -- | -- | -0.7858 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -27.73m | 22.06m | 8.00 | -- | 1.70 | -- | -- | -4.77 | -4.77 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -114.20 | -95.57 | -159.68 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Unity Biotechnology Inc | 0.00 | -19.05m | 22.24m | 19.00 | -- | 1.57 | -- | -- | -1.14 | -1.14 | 0.00 | 0.8394 | 0.00 | -- | -- | 0.00 | -32.73 | -47.21 | -38.49 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -6.08m | 22.57m | 4.00 | -- | 3.78 | -- | 347.19 | -0.8441 | -0.8441 | 0.009 | 0.6860 | 0.0107 | -- | -- | 16,250.00 | -100.10 | -- | -117.94 | -- | 92.00 | -- | -9,331.34 | -- | -- | -328.51 | 0.0596 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Ibio Inc | 225.00k | -15.44m | 23.30m | 16.00 | -- | 1.03 | -- | 103.56 | -7.74 | -10.98 | 0.0586 | 2.47 | 0.0064 | -- | 0.4907 | 14,062.50 | -44.16 | -27.69 | -69.38 | -33.13 | -- | -- | -6,863.56 | -1,862.11 | -- | -- | 0.0689 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| Palatin Technologies, Inc. | 4.49m | -29.74m | 23.46m | 30.00 | -- | -- | -- | 5.22 | -1.97 | -1.97 | 0.2981 | -0.0062 | 0.3131 | 0.3713 | 3.08 | 149,669.70 | -207.35 | -55.28 | -1,527.99 | -69.08 | 97.83 | -- | -662.26 | -1,359.14 | 1.01 | -- | -- | -- | -7.49 | -40.52 | -23.71 | -- | 3.31 | -- |
| Mira Pharmaceuticals Inc | 0.00 | -12.78m | 23.65m | 3.00 | -- | 10.66 | -- | -- | -0.8562 | -0.8562 | 0.00 | 0.1501 | 0.00 | -- | -- | 0.00 | -373.77 | -- | -737.47 | -- | -- | -- | -- | -- | -- | -3.17 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -31.08m | 24.02m | 25.00 | -- | 1.04 | -- | -- | -0.9317 | -0.9317 | 0.00 | 0.5736 | 0.00 | -- | -- | 0.00 | -79.36 | -- | -104.49 | -- | -- | -- | -- | -- | -- | -263.29 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Lisata Therapeutics Inc | 0.00 | -21.07m | 24.21m | 25.00 | -- | 0.6331 | -- | -- | -2.56 | -2.56 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -40.16 | -45.97 | -43.61 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Cell Source Inc | 0.00 | -6.45m | 24.42m | -- | -- | -- | -- | -- | -0.1627 | -0.1627 | 0.00 | -0.413 | 0.00 | -- | -- | -- | -1,300.91 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -5.14 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 11.17m | -66.17m | 24.56m | 100.00 | -- | 0.286 | -- | 2.20 | -1.74 | -1.74 | 0.2938 | 2.24 | 0.0709 | -- | -- | 111,660.00 | -42.03 | -48.32 | -47.37 | -54.03 | -- | -- | -592.57 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Calidi Biotherapeutics Inc | 0.00 | -24.92m | 24.64m | 41.00 | -- | -- | -- | -- | -5.41 | -5.41 | 0.00 | -1.82 | 0.00 | -- | -- | 0.00 | -279.89 | -- | -- | -- | -- | -- | -- | -- | -- | -27.58 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -39.11m | 25.50m | 35.00 | -- | 1.27 | -- | 2,550.34 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
Data as of Nov 13 2024. Currency figures normalised to Mira Pharmaceuticals Inc's reporting currency: US Dollar USD
5.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cross Staff Investments, Inc.as of 30 Sep 2024 | 365.90k | 2.48% |
| Avantax Planning Partners, Inc.as of 30 Jun 2024 | 118.75k | 0.80% |
| Suncoast Equity Management LLCas of 30 Sep 2024 | 90.00k | 0.61% |
| LPL Financial LLCas of 30 Sep 2024 | 50.00k | 0.34% |
| UBS Securities LLCas of 30 Jun 2024 | 29.55k | 0.20% |
| Citadel Securities LLCas of 30 Jun 2024 | 24.40k | 0.17% |
| First American Bank (Asset Management)as of 30 Sep 2024 | 20.00k | 0.14% |
| The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 2024 | 20.00k | 0.14% |
| Two Sigma Securities LLCas of 30 Jun 2024 | 17.87k | 0.12% |
| Praetorian Wealth Management, Inc.as of 30 Sep 2024 | 17.50k | 0.12% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
